Objective: Two vaccines against cervical cancer are now available. One reduces the burden of genital warts; with the other the model estimates it may have better cross-protection against oncogenic non-vaccine HPV-types. We aimed to understand the extent to which cross-protection could have an equivalent cost impact and the likelihood this would occur. Methods: A population model was developed in Excel® to evaluate the expected annual healthcare cost of protecting cervical diseases with vaccines against specific HPV-types. The type-specific vaccine effect was assessed on the number of abnormal pap smears, pre-cancer lesions, genital warts and cervical cancer cases prevented. Vaccine effect was calculated by multiplying the proportion of HPV-types per lesion, as reported in the literature, by a range of vaccine efficacy values. A healthcare perspective was selected, with unit costs (2006 CDN$) for each intervention obtained from official tariff data. No discounting was applied as results are reported over a one-year period after reaching steady-state level of vaccination. Multiple probabilistic sensitivity analysis was performed to estimate the distribution of the cost difference between the two vaccines by running 5000 iterations with @Risk® software in Excel® (normal distributions for vaccine efficacy, uniform distributions for HPV typing and costs). Results: Multiple probabilistic sensitivity analysis showed an average annual cost difference of $9.3M (CDN) (95% CI: -$10M, +$43M) in favor of cross-protection over genital warts protection. Cross-protection provided additional cost saving with an 86.3% probability. An efficacy for additional cross protection of around 12% would achieve cost neutrality. The difference in cost was most sensitive to vaccine efficacy of cross-protection, the proportion of non-vaccine oncogenic HPV-types in CIN1, and the unit cost of treating CIN1. Conclusion: A vaccine with additional cross-protection of at least 12% is likely to offset the costs associated with the protection against genital warts in the Canadian health care system.